NO341404B1 - Monoklonale antistoffer og fremgangsmåte for fremstilling derav, samt hybridom, polynukleotid, vektor, celle og sammensetning for behandling av kreft - Google Patents

Info

Publication number

NO341404B1

NO341404B1 NO20110647A NO20110647A NO341404B1 NO 341404 B1 NO341404 B1 NO 341404B1 NO 20110647 A NO20110647 A NO 20110647A NO 20110647 A NO20110647 A NO 20110647A NO 341404 B1 NO341404 B1 NO 341404B1

Authority

NO

Norway

Prior art keywords

psca

antibody

protein

cancer

cells

Prior art date

2004-05-28

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004027 cell Anatomy 0.000 title claims description 191
• 239000002157 polynucleotide Substances 0.000 title claims description 67
• 102000040430 polynucleotide Human genes 0.000 title claims description 67
• 108091033319 polynucleotide Proteins 0.000 title claims description 67
• 239000000203 mixture Substances 0.000 title claims description 53
• 239000013598 vector Substances 0.000 title claims description 48
• 210000004408 hybridoma Anatomy 0.000 title claims description 17
• 206010028980 Neoplasm Diseases 0.000 title description 198
• 238000000034 method Methods 0.000 title description 167
• 201000011510 cancer Diseases 0.000 title description 118
• 238000011282 treatment Methods 0.000 title description 65
• 238000002360 preparation method Methods 0.000 title description 8
• 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 576
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 92
• 108091007433 antigens Proteins 0.000 claims description 89
• 102000036639 antigens Human genes 0.000 claims description 89
• 239000000427 antigen Substances 0.000 claims description 88
• 230000027455 binding Effects 0.000 claims description 85
• 239000012634 fragment Substances 0.000 claims description 70
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 19
• 238000004519 manufacturing process Methods 0.000 claims description 13
• 239000003550 marker Substances 0.000 claims description 8
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 101710120463 Prostate stem cell antigen Proteins 0.000 description 626
• 108090000623 proteins and genes Proteins 0.000 description 221
• 108090000765 processed proteins & peptides Proteins 0.000 description 219
• 102000004169 proteins and genes Human genes 0.000 description 196
• 235000018102 proteins Nutrition 0.000 description 190
• 102000004196 processed proteins & peptides Human genes 0.000 description 127
• 241000282414 Homo sapiens Species 0.000 description 103
• 230000014509 gene expression Effects 0.000 description 100
• 235000001014 amino acid Nutrition 0.000 description 68
• 229940024606 amino acid Drugs 0.000 description 65
• 150000001413 amino acids Chemical class 0.000 description 64
• 108020004414 DNA Proteins 0.000 description 63
• 150000007523 nucleic acids Chemical class 0.000 description 62
• 102000039446 nucleic acids Human genes 0.000 description 58
• 108020004707 nucleic acids Proteins 0.000 description 58
• 108020004999 messenger RNA Proteins 0.000 description 53
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 52
• 239000000523 sample Substances 0.000 description 52
• 210000001519 tissue Anatomy 0.000 description 52
• 229960005486 vaccine Drugs 0.000 description 52
• 206010060862 Prostate cancer Diseases 0.000 description 50
• 239000002299 complementary DNA Substances 0.000 description 49
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 48
• 229920001184 polypeptide Polymers 0.000 description 48
• 241001465754 Metazoa Species 0.000 description 43
• 230000002163 immunogen Effects 0.000 description 43
• 239000000047 product Substances 0.000 description 41
• 230000001225 therapeutic effect Effects 0.000 description 36
• 210000002307 prostate Anatomy 0.000 description 35
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
• 201000010099 disease Diseases 0.000 description 32
• 210000002443 helper t lymphocyte Anatomy 0.000 description 32
• 229940127089 cytotoxic agent Drugs 0.000 description 30
• 210000004443 dendritic cell Anatomy 0.000 description 27
• 230000028993 immune response Effects 0.000 description 27
• 108020004705 Codon Proteins 0.000 description 26
• 238000003556 assay Methods 0.000 description 26
• 230000000694 effects Effects 0.000 description 26
• 239000003795 chemical substances by application Substances 0.000 description 24
• 239000002773 nucleotide Substances 0.000 description 24
• 125000003729 nucleotide group Chemical group 0.000 description 24
• 238000011579 SCID mouse model Methods 0.000 description 23
• 239000012472 biological sample Substances 0.000 description 23
• 238000002512 chemotherapy Methods 0.000 description 23
• 238000001514 detection method Methods 0.000 description 23
• 230000005855 radiation Effects 0.000 description 23
• 238000006467 substitution reaction Methods 0.000 description 23
• 230000000875 corresponding effect Effects 0.000 description 22
• 241000699670 Mus sp. Species 0.000 description 21
• 210000001744 T-lymphocyte Anatomy 0.000 description 21
• 239000002246 antineoplastic agent Substances 0.000 description 20
• 239000003814 drug Substances 0.000 description 20
• 230000012010 growth Effects 0.000 description 20
• 230000004044 response Effects 0.000 description 20
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
• 230000034994 death Effects 0.000 description 19
• 231100000517 death Toxicity 0.000 description 19
• 230000000295 complement effect Effects 0.000 description 18
• 230000005847 immunogenicity Effects 0.000 description 18
• 210000004881 tumor cell Anatomy 0.000 description 18
• 241001529936 Murinae Species 0.000 description 17
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 17
• 239000003153 chemical reaction reagent Substances 0.000 description 17
• 102000050405 human PSCA Human genes 0.000 description 17
• 239000003446 ligand Substances 0.000 description 17
• 230000001404 mediated effect Effects 0.000 description 17
• 210000000056 organ Anatomy 0.000 description 17
• 239000000126 substance Substances 0.000 description 17
• 238000012360 testing method Methods 0.000 description 17
• 230000004071 biological effect Effects 0.000 description 16
• 150000001875 compounds Chemical class 0.000 description 16
• 230000006870 function Effects 0.000 description 16
• 230000005764 inhibitory process Effects 0.000 description 16
• 230000004614 tumor growth Effects 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 238000013459 approach Methods 0.000 description 15
• 230000003053 immunization Effects 0.000 description 15
• 230000004048 modification Effects 0.000 description 15
• 238000012986 modification Methods 0.000 description 15
• 238000002560 therapeutic procedure Methods 0.000 description 15
• 206010005003 Bladder cancer Diseases 0.000 description 14
• 206010009944 Colon cancer Diseases 0.000 description 14
• 108091034117 Oligonucleotide Proteins 0.000 description 14
• 239000003098 androgen Substances 0.000 description 14
• 238000002649 immunization Methods 0.000 description 14
• 238000012216 screening Methods 0.000 description 14
• 150000003384 small molecules Chemical class 0.000 description 14
• 238000001356 surgical procedure Methods 0.000 description 14
• 201000005112 urinary bladder cancer Diseases 0.000 description 14
• 108060003951 Immunoglobulin Proteins 0.000 description 13
• 206010027476 Metastases Diseases 0.000 description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 description 13
• 210000000612 antigen-presenting cell Anatomy 0.000 description 13
• 238000005516 engineering process Methods 0.000 description 13
• 238000002474 experimental method Methods 0.000 description 13
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 13
• 102000018358 immunoglobulin Human genes 0.000 description 13
• 238000011534 incubation Methods 0.000 description 13
• 239000013612 plasmid Substances 0.000 description 13
• 238000001959 radiotherapy Methods 0.000 description 13
• 206010006187 Breast cancer Diseases 0.000 description 12
• 208000026310 Breast neoplasm Diseases 0.000 description 12
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 12
• 125000000539 amino acid group Chemical group 0.000 description 12
• 230000000692 anti-sense effect Effects 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 12
• 230000001419 dependent effect Effects 0.000 description 12
• 230000002401 inhibitory effect Effects 0.000 description 12
• 238000001990 intravenous administration Methods 0.000 description 12
• 210000004072 lung Anatomy 0.000 description 12
• 210000001165 lymph node Anatomy 0.000 description 12
• 201000002528 pancreatic cancer Diseases 0.000 description 12
• 238000011830 transgenic mouse model Methods 0.000 description 12
• 241000124008 Mammalia Species 0.000 description 11
• 239000002671 adjuvant Substances 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 230000010261 cell growth Effects 0.000 description 11
• 239000002254 cytotoxic agent Substances 0.000 description 11
• 102000037865 fusion proteins Human genes 0.000 description 11
• 108020001507 fusion proteins Proteins 0.000 description 11
• 230000001965 increasing effect Effects 0.000 description 11
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 11
• 208000008443 pancreatic carcinoma Diseases 0.000 description 11
• 229940124597 therapeutic agent Drugs 0.000 description 11
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 10
• 102100038358 Prostate-specific antigen Human genes 0.000 description 10
• 238000009175 antibody therapy Methods 0.000 description 10
• 229940022353 herceptin Drugs 0.000 description 10
• 238000009396 hybridization Methods 0.000 description 10
• 210000000987 immune system Anatomy 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• 230000003211 malignant effect Effects 0.000 description 10
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
• 230000008685 targeting Effects 0.000 description 10
• 230000009261 transgenic effect Effects 0.000 description 10
• 230000003442 weekly effect Effects 0.000 description 10
• 108700028369 Alleles Proteins 0.000 description 9
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
• 241000699660 Mus musculus Species 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• 238000012217 deletion Methods 0.000 description 9
• 230000037430 deletion Effects 0.000 description 9
• 238000003780 insertion Methods 0.000 description 9
• 230000037431 insertion Effects 0.000 description 9
• 238000007912 intraperitoneal administration Methods 0.000 description 9
• 229960004452 methionine Drugs 0.000 description 9
• -1 peptidyl phosphonates Chemical class 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 210000002966 serum Anatomy 0.000 description 9
• 241000894007 species Species 0.000 description 9
• 239000003053 toxin Substances 0.000 description 9
• 231100000765 toxin Toxicity 0.000 description 9
• 108700012359 toxins Proteins 0.000 description 9
• 238000002965 ELISA Methods 0.000 description 8
• 206010033128 Ovarian cancer Diseases 0.000 description 8
• 206010061535 Ovarian neoplasm Diseases 0.000 description 8
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
• 230000003321 amplification Effects 0.000 description 8
• 229940022399 cancer vaccine Drugs 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 231100000433 cytotoxic Toxicity 0.000 description 8
• 230000001472 cytotoxic effect Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 230000013595 glycosylation Effects 0.000 description 8
• 238000006206 glycosylation reaction Methods 0.000 description 8
• 238000003384 imaging method Methods 0.000 description 8
• 230000004807 localization Effects 0.000 description 8
• 206010061289 metastatic neoplasm Diseases 0.000 description 8
• 229930182817 methionine Natural products 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 238000003199 nucleic acid amplification method Methods 0.000 description 8
• 230000000069 prophylactic effect Effects 0.000 description 8
• 238000011160 research Methods 0.000 description 8
• 238000003757 reverse transcription PCR Methods 0.000 description 8
• 125000006850 spacer group Chemical group 0.000 description 8
• 238000005406 washing Methods 0.000 description 8
• 101150029707 ERBB2 gene Proteins 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 108700026244 Open Reading Frames Proteins 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 230000024932 T cell mediated immunity Effects 0.000 description 7
• 238000002725 brachytherapy Methods 0.000 description 7
• 210000000481 breast Anatomy 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 208000029742 colonic neoplasm Diseases 0.000 description 7
• 231100000599 cytotoxic agent Toxicity 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 201000005202 lung cancer Diseases 0.000 description 7
• 208000020816 lung neoplasm Diseases 0.000 description 7
• 210000004962 mammalian cell Anatomy 0.000 description 7
• 230000009401 metastasis Effects 0.000 description 7
• 238000012544 monitoring process Methods 0.000 description 7
• 230000002018 overexpression Effects 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 230000001575 pathological effect Effects 0.000 description 7
• 230000002285 radioactive effect Effects 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 230000004083 survival effect Effects 0.000 description 7
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
• 108020004635 Complementary DNA Proteins 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
• 102000007079 Peptide Fragments Human genes 0.000 description 6
• 108010033276 Peptide Fragments Proteins 0.000 description 6
• 241000276498 Pollachius virens Species 0.000 description 6
• 108020004511 Recombinant DNA Proteins 0.000 description 6
• 208000006265 Renal cell carcinoma Diseases 0.000 description 6
• 108700019146 Transgenes Proteins 0.000 description 6
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
• 235000004279 alanine Nutrition 0.000 description 6
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
• 239000000074 antisense oligonucleotide Substances 0.000 description 6
• 238000012230 antisense oligonucleotides Methods 0.000 description 6
• 210000003719 b-lymphocyte Anatomy 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 238000009566 cancer vaccine Methods 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 238000010367 cloning Methods 0.000 description 6
• 230000021615 conjugation Effects 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 239000013604 expression vector Substances 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 238000002991 immunohistochemical analysis Methods 0.000 description 6
• 230000001976 improved effect Effects 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 238000002955 isolation Methods 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000011987 methylation Effects 0.000 description 6
• 238000007069 methylation reaction Methods 0.000 description 6
• 230000003472 neutralizing effect Effects 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 208000023958 prostate neoplasm Diseases 0.000 description 6
• 238000010561 standard procedure Methods 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 210000003932 urinary bladder Anatomy 0.000 description 6
• 238000001262 western blot Methods 0.000 description 6
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
• 208000031404 Chromosome Aberrations Diseases 0.000 description 5
• 108091026890 Coding region Proteins 0.000 description 5
• 102000053602 DNA Human genes 0.000 description 5
• 102000005720 Glutathione transferase Human genes 0.000 description 5
• 108010070675 Glutathione transferase Proteins 0.000 description 5
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
• 238000000636 Northern blotting Methods 0.000 description 5
• 108091005461 Nucleic proteins Proteins 0.000 description 5
• 108700008625 Reporter Genes Proteins 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 238000004422 calculation algorithm Methods 0.000 description 5
• 231100000504 carcinogenesis Toxicity 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 239000011651 chromium Substances 0.000 description 5
• 230000002759 chromosomal effect Effects 0.000 description 5
• 239000000470 constituent Substances 0.000 description 5
• 230000009089 cytolysis Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 230000008030 elimination Effects 0.000 description 5
• 238000003379 elimination reaction Methods 0.000 description 5
• 238000011156 evaluation Methods 0.000 description 5
• 230000036039 immunity Effects 0.000 description 5
• 238000009169 immunotherapy Methods 0.000 description 5
• 238000007901 in situ hybridization Methods 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 5
• 230000003278 mimic effect Effects 0.000 description 5
• 238000010369 molecular cloning Methods 0.000 description 5
• 210000001672 ovary Anatomy 0.000 description 5
• 238000002823 phage display Methods 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 239000001509 sodium citrate Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 229940063683 taxotere Drugs 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 238000011277 treatment modality Methods 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 102000001301 EGF receptor Human genes 0.000 description 4
• 108060006698 EGF receptor Proteins 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
• 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 4
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
• 108091054437 MHC class I family Proteins 0.000 description 4
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
• 108091061960 Naked DNA Proteins 0.000 description 4
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 238000010240 RT-PCR analysis Methods 0.000 description 4
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
• 108010084592 Saporins Proteins 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 238000010162 Tukey test Methods 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 230000001594 aberrant effect Effects 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 125000004429 atom Chemical group 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 229940049706 benzodiazepine Drugs 0.000 description 4
• 150000001557 benzodiazepines Chemical class 0.000 description 4
• 238000001574 biopsy Methods 0.000 description 4
• 229940098773 bovine serum albumin Drugs 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 150000001720 carbohydrates Chemical group 0.000 description 4
• 210000001072 colon Anatomy 0.000 description 4
• 230000003013 cytotoxicity Effects 0.000 description 4
• 231100000135 cytotoxicity Toxicity 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 238000013537 high throughput screening Methods 0.000 description 4
• 230000002998 immunogenetic effect Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 201000010982 kidney cancer Diseases 0.000 description 4
• 230000002147 killing effect Effects 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 208000037819 metastatic cancer Diseases 0.000 description 4
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000004393 prognosis Methods 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000004853 protein function Effects 0.000 description 4
• 230000004850 protein–protein interaction Effects 0.000 description 4
• 238000011002 quantification Methods 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 239000004474 valine Substances 0.000 description 4
• 206010055113 Breast cancer metastatic Diseases 0.000 description 3
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
• 206010057248 Cell death Diseases 0.000 description 3
• VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 108010041986 DNA Vaccines Proteins 0.000 description 3
• 229940021995 DNA vaccine Drugs 0.000 description 3
• 241000702421 Dependoparvovirus Species 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 238000000729 Fisher's exact test Methods 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 3
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 3
• 108091092195 Intron Proteins 0.000 description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 description 3
• 238000012313 Kruskal-Wallis test Methods 0.000 description 3
• 102000043129 MHC class I family Human genes 0.000 description 3
• 229930012538 Paclitaxel Natural products 0.000 description 3
• 108010067902 Peptide Library Proteins 0.000 description 3
• 108091093037 Peptide nucleic acid Proteins 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 description 3
• 206010038389 Renal cancer Diseases 0.000 description 3
• 238000002105 Southern blotting Methods 0.000 description 3
• 206010046865 Vaccinia virus infection Diseases 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 238000000540 analysis of variance Methods 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 238000011230 antibody-based therapy Methods 0.000 description 3
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 229930195731 calicheamicin Natural products 0.000 description 3
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
• 125000002091 cationic group Chemical group 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000006037 cell lysis Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 201000007273 ductal carcinoma in situ Diseases 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 210000005003 heart tissue Anatomy 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 238000010324 immunological assay Methods 0.000 description 3
• 238000001114 immunoprecipitation Methods 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• 229960001592 paclitaxel Drugs 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 230000004962 physiological condition Effects 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 206010038038 rectal cancer Diseases 0.000 description 3
• 201000001275 rectum cancer Diseases 0.000 description 3
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 3
• 210000005084 renal tissue Anatomy 0.000 description 3
• 230000001177 retroviral effect Effects 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 235000004400 serine Nutrition 0.000 description 3
• 230000000391 smoking effect Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 210000001550 testis Anatomy 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000004565 tumor cell growth Effects 0.000 description 3
• 229940035893 uracil Drugs 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 208000007089 vaccinia Diseases 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 108010066676 Abrin Proteins 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 206010048610 Cardiotoxicity Diseases 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
• 108700010070 Codon Usage Proteins 0.000 description 2
• 108091029523 CpG island Proteins 0.000 description 2
• 108091029430 CpG site Proteins 0.000 description 2
• 229920001076 Cutan Polymers 0.000 description 2
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• 241000713666 Lentivirus Species 0.000 description 2
• 108010028921 Lipopeptides Proteins 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 206010027452 Metastases to bone Diseases 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 244000061176 Nicotiana tabacum Species 0.000 description 2
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
• 238000010222 PCR analysis Methods 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000037062 Polyps Diseases 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• 206010071019 Prostatic dysplasia Diseases 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• 230000037453 T cell priming Effects 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 238000012452 Xenomouse strains Methods 0.000 description 2
• 238000002679 ablation Methods 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000000996 additive effect Effects 0.000 description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 description 2
• 238000011319 anticancer therapy Methods 0.000 description 2
• 239000003972 antineoplastic antibiotic Substances 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 239000012867 bioactive agent Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 208000035269 cancer or benign tumor Diseases 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 231100000259 cardiotoxicity Toxicity 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 230000001268 conjugating effect Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 229960003901 dacarbazine Drugs 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 230000002939 deleterious effect Effects 0.000 description 2
• 230000017858 demethylation Effects 0.000 description 2
• 238000010520 demethylation reaction Methods 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 229940000406 drug candidate Drugs 0.000 description 2
• 230000008482 dysregulation Effects 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 210000001671 embryonic stem cell Anatomy 0.000 description 2
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 229940082789 erbitux Drugs 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 238000002710 external beam radiation therapy Methods 0.000 description 2
• 238000011347 external beam therapy Methods 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 238000002825 functional assay Methods 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 230000028996 humoral immune response Effects 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 230000001024 immunotherapeutic effect Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 238000013411 master cell bank Methods 0.000 description 2
• 229960004961 mechlorethamine Drugs 0.000 description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 238000007855 methylation-specific PCR Methods 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 229910052759 nickel Inorganic materials 0.000 description 2
• 238000010606 normalization Methods 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 229940111202 pepsin Drugs 0.000 description 2
• 230000000737 periodic effect Effects 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000037452 priming Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 201000001514 prostate carcinoma Diseases 0.000 description 2
• 230000009145 protein modification Effects 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000010845 search algorithm Methods 0.000 description 2
• 210000000582 semen Anatomy 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 229910052709 silver Inorganic materials 0.000 description 2
• 239000004332 silver Substances 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 238000009121 systemic therapy Methods 0.000 description 2
• 238000012353 t test Methods 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
• 229960001278 teniposide Drugs 0.000 description 2
• 235000008521 threonine Nutrition 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 230000005747 tumor angiogenesis Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• PZFZLRNAOHUQPH-DJBVYZKNSA-N (2r)-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-2-(hexadecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CSC[C@H](OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PZFZLRNAOHUQPH-DJBVYZKNSA-N 0.000 description 1
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
• FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 108010045634 B7 Antigens Proteins 0.000 description 1
• 102000005738 B7 Antigens Human genes 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010061728 Bone lesion Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241001092081 Carpenteria Species 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000052052 Casein Kinase II Human genes 0.000 description 1
• 108010010919 Casein Kinase II Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 240000002627 Cordeauxia edulis Species 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 208000000666 Fowlpox Diseases 0.000 description 1
• 102100039554 Galectin-8 Human genes 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
• 241000696272 Gull adenovirus Species 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 101100226041 Hericium erinaceus eriE gene Proteins 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
• 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 241001289721 Lethe Species 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 208000035346 Margins of Excision Diseases 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027458 Metastases to lung Diseases 0.000 description 1
• 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
• 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
• 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000283283 Orcinus orca Species 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• 241000288049 Perdix perdix Species 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102100038124 Plasminogen Human genes 0.000 description 1
• 101800001357 Potential peptide Proteins 0.000 description 1
• 102400000745 Potential peptide Human genes 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 101710195626 Transcriptional activator protein Proteins 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 206010066901 Treatment failure Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 108010015780 Viral Core Proteins Proteins 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000010317 ablation therapy Methods 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 108700025316 aldesleukin Proteins 0.000 description 1
• 229960005310 aldesleukin Drugs 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
• DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
• LXQXZNRPTYVCNG-YPZZEJLDSA-N americium-241 Chemical compound [241Am] LXQXZNRPTYVCNG-YPZZEJLDSA-N 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 238000003766 bioinformatics method Methods 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 238000000339 bright-field microscopy Methods 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000012219 cassette mutagenesis Methods 0.000 description 1
• 230000008568 cell cell communication Effects 0.000 description 1
• 230000023402 cell communication Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000005859 cell recognition Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 229940030156 cell vaccine Drugs 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 229940030792 clinac Drugs 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 1
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000010924 continuous production Methods 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000002380 cytological effect Effects 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 238000001804 debridement Methods 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 108010028531 enomycin Proteins 0.000 description 1
• 230000006862 enzymatic digestion Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000004996 female reproductive system Anatomy 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 239000013020 final formulation Substances 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000000799 fusogenic effect Effects 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
• 230000037442 genomic alteration Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 229920000140 heteropolymer Polymers 0.000 description 1
• 235000014304 histidine Nutrition 0.000 description 1
• 150000002411 histidines Chemical class 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 102000052972 human La Human genes 0.000 description 1
• 210000002758 humerus Anatomy 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 150000001469 hydantoins Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
• 229940097277 hygromycin b Drugs 0.000 description 1
• 230000006607 hypermethylation Effects 0.000 description 1
• 230000014200 hypermethylation of CpG island Effects 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 238000009802 hysterectomy Methods 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 229940124452 immunizing agent Drugs 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000012151 immunohistochemical method Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 208000030776 invasive breast carcinoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000001325 log-rank test Methods 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000012976 mRNA stabilization Effects 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 229960001786 megestrol Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 108010010621 modeccin Proteins 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 230000009149 molecular binding Effects 0.000 description 1
• ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
• 230000007498 myristoylation Effects 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 229940023146 nucleic acid vaccine Drugs 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 230000030648 nucleus localization Effects 0.000 description 1
• 230000009437 off-target effect Effects 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 230000001582 osteoblastic effect Effects 0.000 description 1
• 230000000010 osteolytic effect Effects 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 229960001744 pegaspargase Drugs 0.000 description 1
• 108010001564 pegaspargase Proteins 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 238000009520 phase I clinical trial Methods 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
• 229960000952 pipobroman Drugs 0.000 description 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920001308 poly(aminoacid) Polymers 0.000 description 1
• 108010054442 polyalanine Proteins 0.000 description 1
• 229920002643 polyglutamic acid Polymers 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 235000013930 proline Nutrition 0.000 description 1
• 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
• 238000011471 prostatectomy Methods 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000002331 protein detection Methods 0.000 description 1
• 230000006916 protein interaction Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 239000000649 purine antagonist Substances 0.000 description 1
• 239000003790 pyrimidine antagonist Substances 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 150000003235 pyrrolidines Chemical class 0.000 description 1
• 238000009801 radical cystectomy Methods 0.000 description 1
• 238000011472 radical prostatectomy Methods 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000002601 radiography Methods 0.000 description 1
• 229910052705 radium Inorganic materials 0.000 description 1
• HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
• 229910052704 radon Inorganic materials 0.000 description 1
• SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 239000013074 reference sample Substances 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 210000000614 rib Anatomy 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 235000017709 saponins Nutrition 0.000 description 1
• 238000013515 script Methods 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 210000001625 seminal vesicle Anatomy 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 150000003355 serines Chemical class 0.000 description 1
• 230000036299 sexual function Effects 0.000 description 1
• 231100000046 skin rash Toxicity 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000007974 sodium acetate buffer Substances 0.000 description 1
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 229940048086 sodium pyrophosphate Drugs 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 238000010972 statistical evaluation Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 239000010907 stover Substances 0.000 description 1
• 230000002311 subsequent effect Effects 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 150000003505 terpenes Chemical class 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 150000003588 threonines Chemical class 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 108091006106 transcriptional activators Proteins 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000003656 tris buffered saline Substances 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 230000001173 tumoral effect Effects 0.000 description 1
• 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• 235000002374 tyrosine Nutrition 0.000 description 1
• 150000003668 tyrosines Chemical class 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 238000009808 unilateral salpingo-oophorectomy Methods 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 201000000334 ureter transitional cell carcinoma Diseases 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 229940125575 vaccine candidate Drugs 0.000 description 1
• 201000010653 vesiculitis Diseases 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1